Seeking Alpha

Stemline Therapeutics (STML +10%) moves up again today after being initiated at Ladenburg...

Stemline Therapeutics (STML +10%) moves up again today after being initiated at Ladenburg Thalmann with a Buy rating and a hefty $36 price target. The stock has been moving steadily higher over the past few weeks, after the FDA granted an Orphan Drug Designation to its treatment for blastic plasmacytoid dendritic cell neoplasm, SL-401.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector